Paul Hudson, Sanofi CEO (Jeremy Paoloni/Abaca/Sipa USA(Sipa via AP Images))

Due to ‘over­whelm­ing de­mand,’ Sanofi and As­traZeneca’s RSV an­ti­body to be in lim­it­ed sup­ply 

Sanofi is ex­pect­ing sup­ply con­straints of its in­fant RSV an­ti­body Bey­for­tus, which it co-de­vel­oped with As­traZeneca, in the first quar­ter of this year. While it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.